LENZ Therapeutics, Inc. (LENZ) stock intrinsic value fair value estimate & owner earnings analysis

LENZ Therapeutics sells VIZZ (aceclidine ophthalmic solution 1.44%), a once-daily eye drop for presbyopia (the age-related loss of close-up vision that affects roughly 128 million people in the U.S.). VIZZ was approved by the FDA in July 2025 - the first aceclidine-based drop approved for this use, with a mechanism designed to shrink the pupil for a sharper, wider-focus image without the ciliary-muscle side effects of older drops - and carries U.S. patent protection to at least 2044. Direct sales began in October 2025, so the company has only a few quarters of real commercial history to judge it by. That history is choppy so far. Roughly 20,000 paid prescriptions were filled in the company's first partial quarter of sales (Q4 2025), which combined with some one-time international licensing payments produced about $19 million of revenue for 2025. Revenue then fell sharply in the first quarter of 2026 before recovering in the second quarter - a pattern consistent with an initial pharmacy/wholesaler stocking bulge followed by a dip back to underlying demand, rather than steady growth. At the same time, cash used in operations for just the first half of 2026 already exceeds the amount used for all of 2025, as the company continues to build out its 88-territory sales force and marketing. That acceleration in spending isn't fully explained by what has been disclosed so far, and it is the single biggest reason to be cautious about assuming a quick path to profitability. On the other side of the ledger, the company is debt-free and held about $292 million of cash and marketable securities at the end of 2025 - several years of funding at the current burn rate - and it has already signed licensing and distribution agreements covering Greater China, South Korea, parts of Southeast Asia, Canada and the Middle East, which can bring in royalties and milestone payments without LENZ having to fund commercialization in those markets itself. Three cases were built from what's already known rather than from a market-recovery story: Bear case: the early sales pattern turns out to be mostly one-time stocking, VIZZ settles into a modest niche against two already-approved rivals (AbbVie's Vuity, which has struggled with weak refill rates, and Orasis's newer Qlosi, plus a generic version of Vuity), and spending stays elevated for longer than the cash pile can comfortably absorb - forcing a dilutive capital raise before the business is self-funding. In this outcome, the company is worth close to nothing per share today, and possibly a bit less once the dilution from that raise is accounted for. Base case: the sales force, already fully hired, gradually becomes more productive; losses stay close to today's level for the next year or two (matching the trend actually seen through mid-2026, not a hoped-for near-term improvement) before narrowing as revenue grows against a largely fixed cost base, reaching break-even around 2031 and settling into a profitable, if modest, specialty eye-care business protected by patents into the mid-2040s. On this path the shares are worth roughly $22 today. Bull case: the U.S. launch executes well against the specific group of about 15,000 high-prescribing eye-care professionals the company has targeted, the signed international licenses start contributing meaningfully, and the business reaches sustained profitability faster and at a higher level. On this path the shares are worth roughly $47 today. Given how little proven commercial history exists and how wide the gap is between the bear and bull outcomes, the margin-of-safety price is set at a large discount to the base-case estimate - around $9 a share. That price takes effect only after two or three more consecutive quarters of prescription growth that isn't just wholesalers restocking shelves, confirming the underlying demand is real and durable rather than a one-time launch bump.